Our group has shown that OTK c-KIT (N822K mutant in c-KIT receptor tyrosine kinase) induces PARPi resistance in BRCA1/2-deficient AML1-ETO-positive AML [18,29]. This evidence concerns the gene KIT and acute myeloid leukemia.